On September 26, 2025, Harrow Health, Inc. (Nasdaq: HROW) announced that it has entered into an agreement to acquire Melt Pharmaceuticals, Inc., a clinical‑stage company developing non‑opioid, non‑IV sedation therapies for medical procedures.
The deal will bring Melt’s lead investigational therapy, MELT‑300—a sublingual formulation of 3 mg midazolam and 50 mg ketamine—into Harrow’s portfolio. MELT‑300 demonstrated superiority over sublingual midazolam alone (P = 0.009) and placebo (P < 0.0001) in the LOUISE Phase 3 study, and a cardiac safety study showed no alteration of normal heart rhythm.
Melt was a former Harrow subsidiary that was spun off in 2019. The acquisition is subject to customary closing conditions, including approval by Melt stockholders, excluding Harrow and Harrow‑affiliated parties. Harrow CEO Mark L. Baum said the transaction “represents another important step in our mission to deliver innovative, patient‑focused ophthalmic disease‑management solutions that go beyond the limitations of traditional care.”
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.